UCBJY:OTCMKTS
UCB Unsponsored Belgium ADR
114,46 $
arrow_downward
−0,87%(−1,01) 1D
16. okt., 16:00:00 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za UCBJY …
Odpri
114,95 $
Visoka
115,28 $
Nizka
114,23 $
Tržna kapitalizacija
39,39 mrd.
Povprečni promet
53,31 tis.
Promet
70,57 tis.
52-tedenski najvišji tečaj
168,76 $
52-tedenski najnižji tečaj
110,55 $
Beta
0,57
Št. izdanih delnic
389,01 mio.
Št. zaposlenih
9 tis.
Odpri
114,95 $
Visoka
115,28 $
Nizka
114,23 $
Tržna kapitalizacija
39,39 mrd.
Povprečni promet
53,31 tis.
Promet
70,57 tis.
52-tedenski najvišji tečaj
168,76 $
52-tedenski najnižji tečaj
110,55 $
Beta
0,57
Št. izdanih delnic
389,01 mio.
Št. zaposlenih
9 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
ad-hoc-news.de
·
pred 19 urami
UCB revises Bimzelx potential above EUR 7 billion: UCB stock sits 30.28 percent below its high
ad-hoc-news.de
·
pred 1 dnevom
UCB dedicates Georgia campus as UCB stock sits 29.15 percent below its high
Profil
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
Vizitka: UCB Unsponsored Belgium ADR
Generalni direktorJean-Christophe Tellier
Št. zaposlenih9 tis.
Ustanovljeno18. jan. 1928
Sedež-
Sektor-
Spletno mestoucb.com